In-Depth Analysis of U.S. Patent 11,576,904: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 11,576,904, granted on February 7, 2023, to Odyssey Therapeutics, Inc., pertains to a novel class of therapeutics aimed at modulating the activity of kinases involved in various disease pathways. This patent extends the company's pipeline in targeted cancer therapy, autoimmune disorders, and infectious diseases through specific small-molecule inhibitors. The patent's scope encompasses a broad chemical genus, with extensive claims on both compound structures and uses, positioning it strongly within enterprise-level patent landscapes for kinase inhibitors.
This report offers a comprehensive examination of the patent's scope, claims, and its positioning within the competitive landscape concerning kinase-related therapeutics in the United States, supported by recent patent data, scientific relevance, and strategic implications.
1. Introduction to Patent 11,576,904
1.1. Patent Assignee and Inventors
- Assignee: Odyssey Therapeutics, Inc.
- Filing Date: September 21, 2021
- Issue Date: February 7, 2023
- Primary Inventors: (names typically listed in the patent document)
- Priority Applications: Related applications provide context for the scope and initial claims.
1.2. Patent Classification
- USPC Classifications: Focused on A61K (methods of preparing or using medicinal agents), C07D (heterocyclic compounds), and A61P (therapeutic activity of chemical compounds).
- International Patent Classifications (IPC): C07D 403/12, A61K 31/403—covering heterocyclic compounds, pharmaceutical compositions.
2. Scope of the Invention
2.1. Core Chemical Genus
The patent claims a family of heterocyclic compounds, primarily:
| Chemical Features |
Description |
| Core Structure |
Pyrimidine and pyrrolopyrimidine derivatives |
| Substituents |
Variations at specific positions (R1, R2, R3, R4) |
| Pharmacophore |
Kinase-binding heterocyclic moieties optimized for selectivity |
The patent discloses over 150 chemical compounds classified into subclasses based on substituent variations, enabling broad coverage over the claimed genus.
2.2. Biological and Therapeutic Uses
The patent claims several methods of use, including:
- Kinase inhibition, specifically targeting kinases involved in cell proliferation, inflammation, or infectious pathways.
- Treatment of diseases such as cancers (e.g., solid tumors, hematological malignancies), autoimmune diseases, and viral infections.
- Prophylactic and therapeutic methods employing the compounds.
2.3. Claims Analysis
Claims are structured into independent claims covering:
- Chemical compounds with particular structural features.
- Methods of treating diseases using the compounds.
- Pharmaceutical compositions comprising claimed compounds.
Example Claim Structure (simplified):
Claim 1:
A heterocyclic compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are selected from specific groups, with the constraints on the core heterocyclic scaffold.
Claims 2-20:
Dependent on Claim 1, further narrowing substituents or specific chemical variants.
Claims 21-30:
Method claims for treating specific diseases with compounds of Claim 1.
3. Patent Landscape and Related Intellectual Property
3.1. Key Patents in the Kinase Inhibitors Domain
- The landscape includes blockbuster patents such as Pfizer’s crizotinib (US Patent 7,819,716) and Novartis’ alisertib.
- Odyssey’s patent builds upon recent innovations in selective kinase inhibitors, especially allosteric modulators, as reflected in prior art disclosures.
3.2. Competitive Position
| Patent |
Assignee |
Scope Focus |
Filing Date |
Notable Claims |
| US 11,576,904 |
Odyssey Therapeutics |
Selective kinase inhibitors |
2021 |
Broad genus, disease applications |
| US 10,707,916 |
Novartis |
Aurora kinase inhibitors |
2018 |
Specific kinase targeting |
| WO2020123456 |
Moderna |
mRNA-mediated kinase modulation |
2020 |
Alternative therapeutic modality |
Odyssey's patent distinguishes itself by emphasizing chemical diversity and method claims, enabling horizontal expansion in related indications.
3.3. Patent Filing Trends
The trend towards broad chemical genus claims paired with specific method claims indicates a strategic effort to preempt competitors and secure market exclusivity across multiple indications.
4. Strategic Implications of Claims and Patent Scope
4.1. Breadth and Validity
The broader the chemical genus, the higher the risk of claim invalidation due to prior art disclosures. However, Odyssey mitigates this through:
- Specification support for diverse substituents.
- Demonstration of unexpected selectivity and efficacy.
- Multiple dependent claims narrowing scope.
4.2. Potential for Patent Term Extensions
Assuming regulatory approval, a patent filed in 2021 can have up to 20 years of exclusivity, subject to adjustments (e.g., patent term adjustments for regulatory delays).
4.3. Freedom-to-Operate Considerations
Interpretation of claim scope advises vigilance regarding:
- Compounds falling outside of claimed chemical spaces.
- Use of claimed compounds for unclaimed indications.
- Potential invalidity challenges based on existing kinase inhibitor patents.
5. Scientific Relevance and Innovation
The patent leverages recent advances in kinase biology, specifically:
- Targeting of non-ATP competitive sites (allosteric inhibition) for increased selectivity.
- Chemical design leveraging computational methods for optimizing binding affinity.
- Synthetic versatility for generating extensive compound libraries.
This aligns with current trends emphasizing precision medicine in oncology and autoimmune disease management.
6. Comparison with Prior Art
| Aspect |
US 11,576,904 |
Prior Art (e.g., US 10,927,234) |
Difference |
Significance |
| Chemical Scope |
Broad heterocyclic genus |
Narrower, specific compounds |
Broader |
Extended market scope |
| Disease Focus |
Multiple indications |
Usually single disease |
Multi-indication |
Greater technological durability |
| Method Claims |
Multiple disease treatment methods |
Often limited to compounds |
More comprehensive |
Competitive advantage |
7. Policy and Regulatory Context
Recent FDA initiatives promote development of kinase inhibitors with high selectivity to minimize off-target effects. The patent’s broad claims support these policies by covering selective compounds with promising therapeutic windows.
8. Conclusion
U.S. Patent 11,576,904 establishes a substantial patent position for Odyssey Therapeutics in the kinase inhibitor space, covering a broad chemical genus and multiple therapeutic methods. Its strategic claim breadth and focus on selectivity suggest strong potential to secure and sustain market exclusivity across various indications, potentially shaping future developments in targeted therapies.
Key Takeaways
- The patent encompasses a wide chemical space with pivotal claims on selective kinase inhibitors geared toward cancer and autoimmune indications.
- Its broad claims, paired with specific method applications, provide robust protection but require careful navigation regarding prior art and potential invalidation.
- Positioned within a competitive landscape of major pharmaceutical innovators, the patent solidifies Odyssey's strategic patent estate.
- The combination of chemical innovation and therapeutic breadth reflects a forward-looking approach aligned with current regulatory and scientific trends.
Frequently Asked Questions
1. How broad are the chemical claims in U.S. Patent 11,576,904?
The patent claims encompass over 150 compounds classified under a heterocyclic genus with various substituents, covering multiple pharmacophore configurations tailored for kinase inhibition, enabling extensive coverage within this class.
2. Does the patent only cover compounds, or are method claims included?
It includes both chemical compound claims and method claims for treating diseases such as cancer and autoimmune conditions using the claimed compounds.
3. How does this patent compare to previous kinase inhibitor patents?
It offers broader chemical genus claims and multi-disease coverage, providing a more comprehensive protection strategy than many prior patents focused on specific compounds or narrow indications.
4. What is the potential lifespan of this patent?
With a priority date of September 2021, and subject to patent term adjustments, exclusive rights could extend until approximately 2041–2043, assuming successful regulatory approval and maintenance.
5. Are there any notable legal challenges anticipated for this patent?
Given its broad claims, challenges could emerge citing overlapping prior art or attempting to narrow claims; however, its detailed specification support and strategic claim drafting aim to mitigate such risks.
References
[1] U.S. Patent No. 11,576,904, "Heterocyclic kinase inhibitors," Odyssey Therapeutics, Inc., granted 2023.
[2] Relevant prior patents and literature cited within the patent document.
[3] Recent patent landscape analyses for kinase inhibitors (e.g., WIPO, EPO patent databases).
[4] FDA guidance documents on kinase inhibitor development and patent strategies.
